The UK and US have finalized a landmark bilateral deal that will guarantee zero tariffs on UK medicine exports entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to increase spending on medicines through the NHS. This move guarantees that import taxes on these crucial products will remain at nothing for a duration of three years.
This agreement comes after previous threats to significantly raise tariffs on patented pharmaceutical imports, with increases floated reaching 100%.
"This agreement with the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. medicine commerce," a release noted.
Economic Impact
Pharmaceuticals constitute one of the the United Kingdom's most significant exports to the US, which is clearly the largest buyer for large British pharmaceutical firms.
Trade data indicate that in the one-year period to the end of the third quarter, the UK exported drugs worth billions to the US. This value accounted for a significant portion of total UK exports in that span.
"This agreement protects jobs, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement entails several key pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be restricted at 15%. In the past, repayments were more than twenty percent.
Recent Tensions
The deal takes place against a ongoing row between the drug companies and the ministers over medicine costs and NHS adoption.
The disagreement were exacerbated by assertions that American patients were paying several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the last ten years.
